
A no-compromise treatment for enlarged Prostate (BPH).

No Sexual Side-effects.
No Urethra.
In-Office.



VIVIFI MEDICAL | MEDTECH INNOVATOR | PEPPERDINE GRAZIADIO BUSINESS SCHOOL | MOST Fundable COMPANIES

Benign Prostate Hyperplasia (BPH) is a nightmare for Aging Men

"I plan my day around bathrooms, and my nights around not sleeping" – BPH patient*

2 in 3
Men over 60 affected

3M
Delay or Abandon treatment

$7B
US Addressable Market Gap

Current Patient Care Pathway


Medication (5M/year)

- Sexual Dysfunction
- Bladder dysfunction
- Dizziness
- Temporary symptom relief

3M/year
Patient Dropoff

Transurethral Procedure (300K/year)

- Sexual Dysfunction
- Urinary complications
- Repeat surgery (up to 50% in 5 years)
- Invasive



Our Solution

The first and only treatment that addresses BPH at the source. Without the side-effects.

Reduce testosterone-rich blood flow to induce prostate tissue regression.

Device: Hair-thin needles close target vessels 3mm below the skin. No implant.




Vivifi Medical. All rights reserved.

Vivifi is Uniquely Positioned to Treat BPH in the Only Way Patients Want

Most go in through the Urethra.
We *barely* break the skin.

No Sexual side-effects.
No Urethra.
In-office.



The Right Team for This Problem



Tushar Sharma, PhD
Founder & CEO

Experience across 5 Medtech startups.
Former Johnson & Johnson and Intel



Steve Nguyen
Head, R&D

20+ Yrs developing electrosurgical systems.
Former Johnson & Johnson, Ethicon, Alcon



Dan Root, MD
Head, Medical Affairs

Physician and entrepreneur with 2 exits,
20 yrs of experience in bringing healthcare solutions to improve patients' lives.

Backed by Urology & MedTech's Top names



Marshall Stoller, MD

UCSF Department of Urology

- Professor & Vice Chair, Urology, UCSF
- KOL for Urology, Overactive Bladder
- Karl Storz lifetime achievement award



Eric Klein, MD

Cleveland Clinic

- Emeritus Chairman, Prof of Surgery, Glickman Urological and Kidney Institute, Cleveland Clinic



Ricardo Gonzalez, MD

HOUSTON Methodist LEADING MEDICINE

- Urologist at Houston Methodist
- Internationally recognized
- KOL for BPH technologies



Steven Kaplan, MD

Mount Sinai

- Leading BPH specialist; 1000+ publications
- $6B+ in MedTech company value created
- President, AUA Innovation Nexus



Stanton Rowe

CEO, Nidus Biomedical

- Introduced TAVR (acquired by Edwards)
- Market cap > $10B
- Raised $250M from Deerfield for NXT



Mike Kujak, MBA

CEO, Francis Medical

- Former GM, Prostate Health at AMS ($1.6B exit to Boston Scientific)
- Former NxThera executive (Rezūm; $400M Boston Scientific exit)

Vivifi Medical. All rights reserved.

Traction

Strong Clinical Outcomes

N = 9 Proof-of-concept study
Symptom improvement comparable or better than MIST treatments (UroLift, Rezum, Optilume)
No sexual or urinary side effects

$4.4M Raised Previously

$2M Seed Round, $2.4M non-dilutive
Notable investors: Life Science Angels, TMC Venture Fund, RobinHood Ventures, Elevate Capital
Supported by NSF, NIH, and business grant awards

Validated Strategic Interest

Recent acquisitions in the BPH space demonstrate strong strategic appetite, including acquisitions of UroLift ($1.1B), Rezum ($406M), and Optilume ($600M).On average, 9X exit multiple (Total Capital). Potential for **25-30X ROI for Seed+ investors (current round).**

"This could be a paradigm shifting approach to treat BPH and become the new first-line therapy."

Marshall Stoller, MD
Professor of Urology | Former Vice Chair, Department of Urology
University of California San Francisco (UCSF)

Raising $3M Seed+ | Funds the full path to Series A | $2.1M Closed

Q2 2026

COMPLETED

Build 40 Devices

Manufacture prototype units for clinical use. Establish QA protocols.

Q3 2026

OCTOBER 2026

10-Patient FIH Study

Safety & feasibility validation.

Q4 2026

NEXT-GEN DEVICE

Next-Gen Device Build

Manufacture 150-200 units in for the next Clinical Study.

H2 2027

NEXT STUDY

30-Patient Pre-Pivotal Initiation

Devices and Regulatory approvals needed to initiate next study.

H2 2027

SERIES A TRIGGER

6-Month Readout

6-month follow-up data from FIH cohort closes the Series A raise.

$3M Note to fund milestones to Series A

Join us to disrupt the standard of care and rewrite the treatment pathway for BPH.

info@vivifimedical.com
vivifimedical.com

VIVIFI MEDICAL

Startup: Vivifi Medical

https://iitstartups.org/us-demoday-cohort-15/

Vivifi Medical is fixing the root cause of BPH (enlarged prostate) without surgery, implants, or sexual risk.

SCAN

https://zfrmz.com/p19jyuetieRIM6wRPsfF



Tushar Sharma

Founder & CEO

tushar@vivifimedical.com

+1 971 334 6157

https://www.linkedin.com/in/stushar/

https://superhuman.com/book/11VbFYr5rx0OotnsZt/1YAFL